Skip to main content
OpenTrials
Completed

NCT Number: NCT00822731

Samsung Medical Center-Lymphoma Cohort Study

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

15 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

About this study

Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess following factors which amy probably affect the treatment outcome and the risk of treatment-related morbidity.

  • Biologic factors associated with the aggressiveness of lymphoma
  • molecular markers in serum, cytogenetic markers
  • Factors associated with the risk of treatment-related morbidity
  • comorbidity, nutrition status, performance status, quality of life at diagnosis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who were diagnosed as lymphoma
  • Over 15 years old
  • Patients who agreed the enrollment of study
  • Informed consent for sampling

Exclusion criteria

  • Patients who do not want to join the study

Treatment and study plan

Chemotherapy with or without radiotherapy

Drug

Treatment regimen will be determined by the sub-type of lymphoma

Other names: Chemotherapy:CHOP, RCHOP, (R)HyperCVAD

Primary outcomes

  1. all cause mortality

    Time frame: 5 years

Secondary outcomes

  1. Treatment response

    Time frame: after completion of primary therapy

  2. Rate of occurrence of toxicity

    Time frame: 2 years from the start of the 1st therapy

  3. Treatment-related morbidity

    Time frame: within 60 days from the previous therapy

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Development of a Predictive Model for Treatment Outcome and Treatment-related Morbidity in a Prospective Cohort Study of Patients With Lymphoma

Acronym: SMC-LCS

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Jan 14, 2009
Registry last updated
May 23, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.